ASweetLife Team, Author at ASweetLife

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients...

New Cigarette Health Warnings Unveiled

The U.S. Food and Drug Administration (FDA) today unveiled nine graphic health warnings which will be required to appear on every pack of cigarettes sold in the United States and in every cigarette advertisement beginning no later than September 2012. This bold measure will help prevent children from smoking, encourage adults who do to quit, and ensure every American understands the dangers of smoking. The new FDA warnings represent the most significant changes to cigarette labels in more than 25 years...

U.S. Supreme Court Justice Sonia Sotomayor to Speak At JDRF 2011 Children’s Congress

U.S. Supreme Court Justice Sonia Sotomayor will meet with 150 children and teens with type 1 diabetes during the 2011 Children’s Congress which takes place June 20-22 in Washington D.C. Justice Sotomayor, who was diagnosed with type 1 diabetes at the age of eight, will share her experiences of type 1 diabetes as she's pursued her professional dreams. Organized by the Juvenile Diabetes Research Foundation (JDRF), the “Role Models with Type 1 Diabetes”...

Long Term Use of Diabetes Drug Actos May Increase Risk of Cancer

The U.S. Food and Drug Administration (FDA) issued a safety announcement informing the public that use of the type 2 diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines...

New Type 2 Diabetes Treatment Tradjenta Now Available in U.S. Pharmacies

The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid following the U.S. Food and Drug Administration (FDA) approval of the drug on May 2, 2011. Tradjenta was approved as a prescription medication to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes...

Novo Nordisk Issues Letter Reminding Healthcare Professionals of Victoza Risks

Novo Nordisk issued a letter reminding healthcare professionals of important safety information about the type 2 diabetes drug Victoza (liraglutide [rDNA origin]). The letter was issued because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza...

Eli Lilly’s Updated Humalog(R) Label Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved Eli Lilly's supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]). Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days...

New Animas Combined CGM and Insulin Pump Receives European Approval

The Animas corporation announced that Animas Vibe, the first and only continuous glucose monitoring (CGM)-enabled insulin pump system with Dexcom G4™ CGM technology, received the CE Mark of approval. The Animas® Vibe combines the features of an Animas insulin pump with the convenience of Dexcom CGM, which is the only sensor approved for up to seven days of wear...

Sanofi Releases More Results from Type 2 Diabetes Drug Lyxumia (lixisenatide) Study

Sanofi has released additional positive results from the global GetGoal Phase III development program with Lyxumia (lixisenatide) for the treatment of type 2 diabetes. Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist, was invented by Zealand Pharma and global rights are with Sanofi...

Federal Administration Supports Parents in American Nurses Association vs. O’Connell

The Obama administration has taken a rare step and urged the California courts to allow school employees to administer insulin shots to the state's 14,000 diabetic schoolchildren if no nurses are available, according to the San Francisco Chronicle...